Evidence map›Paper›PMID 31241209›Full record

ArticleJournal of clinical laboratory analysis2019

Overexpression of HPIP as a biomarker for metastasis and prognosis prediction in endometrial cancer patients.

Li Cheng, Tingting Zhao, Shiguo Li, Yao Wang, Hui Fei, Fanling Meng

Abstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Establishment of the Prognosis Predicting Signature for Endometrial Cancer Patient.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Li ChengDepartment of Obstetrics and Gynecology, The Seventh Affiliated Hospital, Sun-Yat sen University, Shenzhen, Guangdong Province, China.
Tingting ZhaoDepartment of Obstetrics and Gynecology, The Seventh Affiliated Hospital, Sun-Yat sen University, Shenzhen, Guangdong Province, China.
Shiguo LiDepartment of Obstetrics and Gynecology, The Seventh Affiliated Hospital, Sun-Yat sen University, Shenzhen, Guangdong Province, China.
Yao WangDepartment of Obstetrics and Gynecology, The Daqing Oilfield General Hospital, Daqing, Heilongjiang, China.
Hui FeiDepartment of Obstetrics and Gynecology, The Seventh Affiliated Hospital, Sun-Yat sen University, Shenzhen, Guangdong Province, China.
Fanling MengDepartment of Gynaecology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.ORCID https://orcid.org/0000-0002-2997-5851

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP) has shown to be overexpressed in several human cancers. The purpose of this study was to explore the expression of HPIP in endometrial cancer (EC) and its associated effects on disease.

methodsA total of 113 EC patients at the Harbin Medical University Cancer Hospital between August 2011 and September 2012 were studied for immunohistochemistry analysis. HPIP expression was detected using real-time reverse transcription PCR, Western blotting, and immunohistochemistry. Prognostic value of HPIP expression was examined using multivariate Cox regression analysis and Kaplan-Meier method.

resultsThe result of Western blotting indicated that HPIP protein expression is significantly high in normal tissues compared to EC tissues (P < 0.001). The expression of HPIP was significantly associated with FIGO stage (P < 0.001), histological grade (P < 0.001), depth of myometrial invasion (P < 0.001), and lymph node metastasis (P = 0.033). Kaplan-Meier analysis demonstrated that there was a significant difference in overall survival and disease-free survival between the two groups of patients stratified by HPIP expression level (log-rank, both P = 0.002). Patients with HPIP high expression had significantly shorter median survival time than those with HPIP low expression. Moreover, results of the multivariate analysis revealed that HPIP expression was an independent prognostic factor for predicting overall survival (P = 0.015) and disease-free survival (P = 0.017) in patients with EC.

conclusionThe present study provides evidence that HPIP predicts EC progression and poor survival, highlighting its potential as a therapeutic target for EC.

Indexed as

Biomarkers, TumorCase-Control StudiesEndometrial NeoplasmsFemaleFollow-Up StudiesHumansIntracellular Signaling Peptides and ProteinsLymphatic MetastasisMiddle AgedNeoplasm InvasivenessPrognosisSurvival RateBiomarkers, TumorHCFC1R1 protein, humanIntracellular Signaling Peptides and Proteinsendometrial cancerhematopoietic pre-B-cell leukemia transcription factorHPIPmetastasisprognosis

Identifiers

PMID31241209
PMCPMC6805295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.